Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.44 |
| ▸ | REN | P00797 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PEPD | P12955 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584217 | 1.00 | ACE (0.44) | ACERENKDM4EF2LMNA | |
| SCHEMBL58639 | 1.00 | ACE (0.44) | ACERENKDM4EF2LMNA | |
| SCHEMBL1432569 | 0.94 | ACE (0.49) | ACERENKDM4EF2LMNA | |
| SCHEMBL1881293 | 0.94 | ACE (0.49) | ACERENKDM4EF2LMNA | |
| SCHEMBL1432340 | 0.94 | ACE (0.49) | ACERENKDM4EF2LMNA | |
| SCHEMBL5701892 | 0.85 | ACE (0.40) | ACERENKDM4EF2LMNA | |
| SCHEMBL5701910 | 0.85 | ACE (0.40) | ACERENKDM4EF2LMNA | |
| SCHEMBL2091581 | 0.85 | ACE (0.40) | ACERENKDM4EF2LMNA | |
| SCHEMBL26997633 | 0.85 | ACE (0.53) | ACERENKDM4EF2LMNA | |
| SCHEMBL18897108 | 0.85 | ACE (0.41) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | claimed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | claimed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2024-11-26 | — | — | US | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-11793771-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793771-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230322731-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2009047264-A1 | SPIROPYRROLIDINES AND THEIR USE AGAINST HCV AND HIV INFECTION | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-03-29 | — | — | US | disclosed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | disclosed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | disclosed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0991658-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322731-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ACE 2805/4885REN 1607/4885KDM4E 738/4885 |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | ACE 2660/4885REN 2382/4885KDM4E 2695/4885 |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | ACE 2805/4885REN 1607/4885KDM4E 738/4885 |
| US-11793771-B2 | Immunomodulator compounds | IL2, IL2RA, C3AR1 | ACE 2825/4885REN 754/4885KDM4E 3541/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | ACE 2305/4885REN 3862/4885KDM4E 2204/4885 |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | ACE 2305/4885REN 3862/4885KDM4E 2204/4885 |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | ACE 2305/4885REN 3862/4885KDM4E 2204/4885 |
| US-20060270606-A1 | Dolastatin 15 derivatives | DDOST, DBI, DAO | ACE 2660/4885REN 2382/4885KDM4E 2695/4885 |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | PHKG1, MAP3K19, MAP3K20 | ACE 3027/4885REN 4118/4885KDM4E 1503/4885 |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | ACE 2660/4885REN 2382/4885KDM4E 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.